EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy

Taewan Kim iD, Jaesung Ryu iD, Hyejeong Kong iD, Beamjun Park iD, Kwangseock Kim iD, Eunjung Yang iD, Taesung Ahn iD, Seob Jeon iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27031194 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Taewan Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Future Innovation Medical Research Center, Soonchunhyang University Cheonan Hospital, Cheonan 31151, Republic of Korea. Hauptthemen laut MEDLINE: Hepatocyte Nuclear Factor 3-alpha, Ovarian Neoplasms, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Trade, Industry & Energy (MOTIE, Korea)., Soonchunhyang University Research Fund, Ministry of Trade, Industry & Energy (MOTIE, Korea)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to elucidate the oncogenic role of FOXA1(forkhead box A1) in ovarian cancer and to evaluate its potential as both a therapeutic target and a diagnostic biomarker. We further investigated whether FOXA1 inhibition could enhance responsiveness to immune checkpoint blockade and overcome chemoresistance. A total of seventy-six ovarian tissue samples were analyzed, including nine normal, thirty-four benign, and thirty-three malignant specimens. IHC (immunohistochemistry) staining was performed to assess FOXA1 expression and its correlation with tumor stage. Functional studies were conducted using FOXA1 siRNA in SK-OV3 and HEYA8 cell lines. Changes in cell proliferation, migration, invasion, and wound-healing ability were evaluated following FOXA1 silencing. Quantitative RT-PCR was used to measure the expression of FOXA1 and EMT (epithelial–mesenchymal transition)-related genes. The effects of FOXA1 inhibition on sensitivity to carboplatin and the immune checkpoint inhibitor atezolizumab were also examined. IHC analysis revealed significant differences in FOXA1 expression among normal, benign, and malignant tissues, with levels correlating with tumor stage. FOXA1 silencing significantly reduced proliferation and decreased migration and invasion by 60–80%, accompanied by marked downregulation of EMT-related genes. Moreover, FOXA1 inhibition enhanced atezolizumab responsiveness and reduced carboplatin resistance in ovarian cancer cells. In summary, FOXA1 acts as an oncogenic driver in ovarian cancer, promoting proliferation, invasion, and EMT activation. Its overexpression correlates with disease progression, supporting its potential as a biomarker and therapeutic target. Targeting FOXA1 could enhance immunotherapy efficacy and help overcome chemoresistance in ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatocyte Nuclear Factor 3-alphaOvarian NeoplasmsImmunotherapyHumansFemaleCell Line, TumorCell ProliferationEpithelial-Mesenchymal TransitionCell MovementGene Expression Regulation, NeoplasticDrug Resistance, NeoplasmBiomarkers, Tumor

Stichwörter der Autor:innen

FOXA1biomarkerchemoresistanceforkhead box A1immune checkpoint inhibitoroncogeneovarian cancer

Substanzen

Hepatocyte Nuclear Factor 3-alphaFOXA1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Future Innovation Medical Research Center, Soonchunhyang University Cheonan Hospital, Cheonan 31151, Republic of Korea.
  • Department of Medical Life Science, Soonchunhyang University, Asan 31538, Republic of Korea.
  • Department of Gynecology, College of Medicine, Soonchunhyang University Cheonan Hospital, Cheonan 31151, Republic of Korea.
  • Department of Colorectal Surgery, College of Medicine, Soonchunhyang University Cheonan Hospital, Cheonan 31151, Republic of Korea.

ORCID-Profile: Taewan Kim, Jaesung Ryu, Hyejeong Kong, Beamjun Park, Kwangseock Kim, Eunjung Yang, Taesung Ahn, Seob Jeon

Förderung

  • Ministry of Trade, Industry & Energy (MOTIE, Korea).
  • Soonchunhyang University Research Fund
  • Ministry of Trade, Industry & Energy (MOTIE, Korea).

Zitieren

APA

Kim, T., Ryu, J., Kong, H., Park, B., Kim, K., Yang, E., Ahn, T., & Jeon, S. (2026). FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031194

Vancouver

Kim T, Ryu J, Kong H, Park B, Kim K, Yang E, et al. FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031194

BibTeX
@article{Kim2026,
  author = {Kim, Taewan and Ryu, Jaesung and Kong, Hyejeong and Park, Beamjun and Kim, Kwangseock and Yang, Eunjung and Ahn, Taesung and Jeon, Seob},
  title = {FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27031194}
}
Kostenlos starten →